CDMO241220C17500
- 0.00
- 0.000.00%
Avid Bioservices Newsroom
Stephens Maintains Avid Bioservices(CDMO.US) With Hold Rating, Maintains Target Price $12.5
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Hold Rating
Craig-Hallum Sticks to Its Hold Rating for Avid Bioservices (CDMO)
Avid Bioservices Reports 32% Revenue Growth Ahead Of Acquisition
Avid Bioservices: Fiscal Q2 Earnings Snapshot
Avid Bioservices | 10-Q: Q2 2025 Earnings Report
Avid Bioservices Q2 EPS $(0.27) Misses $(0.12) Estimate, Sales $33.50M Miss $33.80M Estimate
Avid Bioservices Suspending Practice of Providing Fincl Guidance in Light of Proposed Transaction >CDMO
Express News | Avid Bioservices Q2 Net Income USD -17.4 Million
Express News | Avid Bioservices Q2 Revenue USD 33.5 Million Vs. IBES Estimate USD 33.8 Million
Express News | Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
Press Release: Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
Ascendia Pharmaceutical Solutions Launched to Meet Drug Development and Manufacturing Needs
Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More
Stephens Downgrades Avid Bioservices(CDMO.US) to Hold Rating, Raises Target Price to $12.5
Craig-Hallum Downgrades Avid Bioservices(CDMO.US) to Hold Rating
Stephens Downgrades Avid Bioservices to Equalweight, Price Target Is $12.50
Understanding Avid Bioservices' (CDMO) Acquisition: Risks and Opportunities
Cannell Capital to Vote Against Avid Biosciences Takeover
Vetter Strengthens Senior Management Team for Further Sustainable Growth